GSK ready to ax hundreds in U.S., as Advair sales plummet.
GSK - NYSE - Nasty Chart, looks like a test of the 2012 low is coming. GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the [...]